DECHENG CAPITAL LLC
Q3 2026 Form 13-F
MENLO PARK, CAYMAN ISLANDS
CIK 0002010850
· CRD 293073
· SEC-registered investment adviser
$685.1M Reported Value Total
DC GLOBAL VENTURES reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $2,728,192,342, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
8 funds
· $2.7B gross asset value
Venture Capital Fund: $2.5B · Hedge Fund: $228.2M
Source: Form ADV filed 2026-03-31
Reported value
$685.1M
Quarter over quarter
-4.0%
Holdings
11
Top-10 concentration
99.9%
Key People
Form ADV owners & control persons
Xiangmin Nmn Cui
MANAGING DIRECTOR
Hongbo Nmn Bao
CHIEF COMPLIANCE OFFICER
Yuheng Nmn Qiu
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 13, 2026 |
| Form | 13F-HR |
| Reported value | $685.1M |
| Positions | 11 |
| Change in reported value | -6.4% |
| New positions | 0 |
| Exited positions | 3 |
| Position turnover | 21.4% |
| Top-10 concentration | 99.9% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
11 | $685.1M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
14 | $731.7M |
|
Q1 2026 13F
Filed May 13, 2026
|
14 | $661.3M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
19 | $743.4M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
23 | $573.2M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
25 | $396.0M |
|
Q1 2025 13F
Filed May 8, 2025
|
27 | $356.5M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $466.2M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
26 | $422.2M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
24 | $326.3M |
|
Q1 2024 13F
Filed May 14, 2024
|
22 | $745.6M |
|
Q4 2023 13F
Filed Feb 12, 2024
|
24 | $357.9M |
Top 11 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $451.7M | 65.93% |
| 2 | NUVB Nuvation Bio Inc. | $145.3M | 21.22% |
| 3 | ACRS Aclaris Therapeutics, Inc. | $21.3M | 3.1% |
| 4 | AARD AARDVARK THERAPEUTICS INC | $20.6M | 3.01% |
| 5 | UPB Upstream Bio Inc. | $14.4M | 2.1% |
| 6 | RCUS Arcus Biosciences, Inc | $11.0M | 1.6% |
| 7 | EQ Equillium Inc. | $7.2M | 1.05% |
| 8 | LYELXXXX Lyell Immunopharma, Inc. | $6.8M | 0.99% |
| 9 | ZNTL Zentalis Pharmaceuticals Inc. | $3.7M | 0.54% |
| 10 | BYSI BeyondSpring Inc. | $2.4M | 0.34% |
| 11 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | $761.5K | 0.11% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.